Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (843)	11/23/1998 10:51:00 AM
From: Henry Niman	Read Replies (3) \| Respond to of 965

I don't think that there is a "pill form". Remicade is a monoclonal antibody (which is a large protein) and therefore must be given via infusion. I think that the earlier versions were distributed in liquid form, while the latter were a dried powder form (which still has to be dissolved in a saline like solution and infused). I think that the problems arose fairly recently when patients who had been treated several years ago were re-infused recently. I have to check, but suspect that the adverse effect is an allergic reaction and the patient is sensitized by the initial injection(s) and then develops a more powerful response when challenged at a later date.